• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors

    9/10/24 7:00:00 AM ET
    $PFE
    $RCKT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PFE alert in real time by email

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the appointment of Mikael Dolsten, M.D., Ph.D., as an independent director to its Board of Directors. Dr. Dolsten is an accomplished industry executive with extensive global pharmaceutical management experience.

    "As an industry-leading pharmaceutical executive, I am very pleased to welcome Mikael to our Board of Directors," said Gaurav Shah, M.D., Chief Executive Officer of Rocket Pharma. "His research and development experience will help advance our leading scientific capabilities and contribute to our mission of developing and delivering potentially transformative treatments for patients."

    Throughout his career, Dr. Dolsten has held several positions and is currently the Chief Scientific Officer, President, Research & Development (R&D) at Pfizer Inc. (NYSE:PFE), focused on advancing gene therapies, small-molecule medicines, biotherapeutics, and vaccines. Dr. Dolsten's previous roles include President of Research at Wyeth and Executive Vice President, Head of Worldwide Research at Boehringer Ingelheim, and senior R&D positions at AstraZeneca, Pharmacia, and Upjohn. He is a member of the Board of Overseers for the Scripps Research Institute and a Foreign Member of The Royal Swedish Academy of Engineering Sciences. He also advised the Obama administration on regulatory and drug development issues and then Vice President Biden's Cancer Moonshot Initiative.

    "Rocket has an impressive pipeline of clinical programs which have shown tremendous promise potentially curing genetic disease," said Dr. Mikael Dolsten, Chief Scientific Officer and President, Pfizer Research & Development. "I am excited to bring my passion and experience to Rocket as it becomes a commercial organization and strives to reach more patients in need."

    About Rocket Pharmaceuticals, Inc.

    Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) is a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of investigational genetic therapies designed to correct the root cause of complex and rare disorders. Rocket's innovative multi-platform approach allows us to design the optimal gene therapy for each indication, creating potentially transformative options that enable people living with devastating rare diseases to experience long and full lives.

    Rocket's lentiviral (LV) vector-based hematology portfolio consists of late-stage programs for Fanconi Anemia (FA), a difficult-to-treat genetic disease that leads to bone marrow failure (BMF) and potentially cancer, Leukocyte Adhesion Deficiency-I (LAD-I), a severe pediatric genetic disorder that causes recurrent and life-threatening infections which are frequently fatal, and Pyruvate Kinase Deficiency (PKD), a monogenic red blood cell disorder resulting in increased red cell destruction and mild to life-threatening anemia.

    Rocket's adeno-associated viral (AAV) vector-based cardiovascular portfolio includes a late-stage program for Danon Disease, a devastating heart failure condition resulting in thickening of the heart, an early-stage program in clinical trials for PKP2-arrhythmogenic cardiomyopathy (ACM), a life-threatening heart failure disease causing ventricular arrhythmias and sudden cardiac death, and a pre-clinical program targeting BAG3-associated dilated cardiomyopathy (DCM), a heart failure condition that causes enlarged ventricles.

    For more information about Rocket, please visit www.rocketpharma.com and follow us on LinkedIn, YouTube, and X.

    Rocket Cautionary Statement Regarding Forward-Looking Statements

    This press release contains forward-looking statements concerning Rocket's future expectations, plans and prospects that involve risks and uncertainties, as well as assumptions that, if they do not materialize or prove incorrect, could cause our results to differ materially from those expressed or implied by such forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. All statements other than statements of historical facts contained in this release are forward-looking statements. You should not place reliance on these forward-looking statements, which often include words such as "could," "believe," "expect," "anticipate," "intend," "plan," "will give," "estimate," "seek," "will," "may," "suggest" or similar terms, variations of such terms or the negative of those terms. These forward-looking statements include, but are not limited to, statements concerning Rocket's expectations regarding the safety and effectiveness of product candidates that Rocket is developing to treat Fanconi Anemia (FA), Leukocyte Adhesion Deficiency-I (LAD-I), Pyruvate Kinase Deficiency (PKD), Danon Disease (DD) and other diseases, the expected timing and data readouts of Rocket's ongoing and planned clinical trials, the expected timing and outcome of Rocket's regulatory interactions and planned submissions, including the timing and outcome of the FDA's review of the additional CMC information that Rocket will provide in response to the FDA's request, the safety, effectiveness and timing of pre-clinical studies and clinical trials, Rocket's ability to establish key collaborations and vendor relationships for its product candidates, Rocket's ability to develop sales and marketing capabilities or enter into agreements with third parties to sell and market its product candidates, Rocket's ability to expand its pipeline to target additional indications that are compatible with its gene therapy technologies, Rocket's ability to transition to a commercial stage pharmaceutical company, and Rocket's expectation that its cash, cash equivalents and investments will be sufficient to funds its operations into 2026. Although Rocket believes that the expectations reflected in the forward-looking statements are reasonable, Rocket cannot guarantee such outcomes. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, Rocket's dependence on third parties for development, manufacture, marketing, sales and distribution of product candidates, the outcome of litigation, unexpected expenditures, Rocket's competitors' activities, including decisions as to the timing of competing product launches, pricing and discounting, Rocket's ability to develop, acquire and advance product candidates into, enroll a sufficient number of patients into, and successfully complete, clinical studies, the integration of new executive team members and the effectiveness of the newly configured corporate leadership team, Rocket's ability to acquire additional businesses, form strategic alliances or create joint ventures and its ability to realize the benefit of such acquisitions, alliances or joint ventures, Rocket's ability to obtain and enforce patents to protect its product candidates, and its ability to successfully defend against unforeseen third-party infringement claims, as well as those risks more fully discussed in the section entitled "Risk Factors" in Rocket's Annual Report on Form 10-K for the year ended December 31, 2023, filed February 27, 2024 with the SEC and subsequent filings with the SEC including our Quarterly Reports on Form 10-Q. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and Rocket undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240910719888/en/

    Get the next $PFE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PFE
    $RCKT

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    Rocket Pharmaceuticals Inc.
    $RCKT
    3/12/2025$50.00Outperform
    BMO Capital Markets
    Rocket Pharmaceuticals Inc.
    $RCKT
    12/30/2024$32.00Outperform
    Wedbush
    Rocket Pharmaceuticals Inc.
    $RCKT
    12/18/2024$29.00Buy
    Jefferies
    Pfizer Inc.
    $PFE
    12/10/2024$29.00Neutral
    BofA Securities
    Pfizer Inc.
    $PFE
    11/15/2024$25.00Underperform
    Wolfe Research
    Pfizer Inc.
    $PFE
    10/25/2024$30.00Neutral
    Citigroup
    Pfizer Inc.
    $PFE
    10/17/2024$32.00Mkt Perform
    Bernstein
    More analyst ratings

    $PFE
    $RCKT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • October 25, 2024 - FDA Roundup: October 25, 2024

      For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

      10/25/24 2:48:21 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for HYMPAVZI issued to PFIZER INC

      Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

      10/15/24 2:57:27 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

      For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

      10/11/24 2:12:15 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PFE
    $RCKT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO Shah Gaurav bought $101,600 worth of shares (20,000 units at $5.08), increasing direct ownership by 3% to 792,680 units (SEC Form 4)

      4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

      4/14/25 6:57:31 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Officer Patel Kinnari bought $99,165 worth of shares (21,099 units at $4.70) (SEC Form 4)

      4 - ROCKET PHARMACEUTICALS, INC. (0001281895) (Issuer)

      4/10/25 4:07:53 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      2/14/25 5:16:36 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PFE
    $RCKT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Rocket Pharmaceuticals Inc.

      SC 13D/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      12/16/24 7:51:51 PM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Rocket Pharmaceuticals Inc.

      SC 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      11/8/24 10:52:38 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Rocket Pharmaceuticals Inc. (Amendment)

      SC 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      4/5/24 9:47:13 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PFE
    $RCKT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Pfizer with a new price target

      Cantor Fitzgerald initiated coverage of Pfizer with a rating of Neutral and set a new price target of $24.00

      4/22/25 8:03:45 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BMO Capital Markets initiated coverage on Rocket Pharmaceuticals with a new price target

      BMO Capital Markets initiated coverage of Rocket Pharmaceuticals with a rating of Outperform and set a new price target of $50.00

      3/12/25 7:31:47 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Rocket Pharmaceuticals with a new price target

      Wedbush initiated coverage of Rocket Pharmaceuticals with a rating of Outperform and set a new price target of $32.00

      12/30/24 7:26:29 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PFE
    $RCKT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $PFE
    $RCKT
    SEC Filings

    See more

    $PFE
    $RCKT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • SEC Form 4 filed by Chairman & CEO Bourla Albert

      4 - PFIZER INC (0000078003) (Issuer)

      5/2/25 1:35:56 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Nora Johnson Suzanne M

      4 - PFIZER INC (0000078003) (Issuer)

      4/28/25 11:55:19 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Blaylock Ronald E

      4 - PFIZER INC (0000078003) (Issuer)

      4/28/25 11:55:18 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Rocket Pharmaceuticals Inc.

      SCHEDULE 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      5/7/25 10:02:21 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Rocket Pharmaceuticals Inc.

      SCHEDULE 13G/A - ROCKET PHARMACEUTICALS, INC. (0001281895) (Subject)

      5/7/25 9:59:37 AM ET
      $RCKT
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Pfizer Inc.

      10-Q - PFIZER INC (0000078003) (Filer)

      5/5/25 4:00:34 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance

      Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment Made Significant Progress Strengthening the R&D Organization On Track to Exceed Net Cost Savings Targets Pfizer Inc. (NYSE:PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1). EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "We continued to execute with focus and discipline against our strategic priorities, including strengthening our R&D organization and driving improved productivity. With the underlying strength of our business, we believe we can be agile in navigating an uncertain and volatile external environment." Dav

      4/29/25 6:45:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer

      Pivotal Phase 3 CREST trial results show a 32% reduction in the risk of disease-related events, including high-grade disease recurrence or progression, with sasanlimab in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) regimen compared to SOC alone Sasanlimab, a subcutaneously administered PD-1 inhibitor, in combination with BCG represents the first potential treatment advancement for BCG-naïve, high-risk non-muscle invasive bladder cancer in more than 30 years Results have been shared with global health authorities to support potential regulatory filings Pfizer Inc. (NYSE:PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an inves

      4/26/25 1:30:00 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guardant Health Announces Strategic Collaboration With Pfizer to Support Development and Commercialization of New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform

      Multi-year global collaboration will utilize Guardant liquid biopsy portfolio in research and clinical applications and evaluate utility of ctDNA for monitoring therapy response Guardant Health, Inc. (NASDAQ:GH), a leading precision oncology company, today announced a strategic collaboration with Pfizer, Inc. (NYSE:PFE), to support the development and commercialization of Pfizer's oncology portfolio using the Guardant Infinity™ smart liquid biopsy platform. Under the multi-year collaboration agreement, Guardant and Pfizer aim to: Utilize Guardant's portfolio of liquid biopsy tests in Pfizer's global clinical studies Evaluate the clinical utility of (a) circulating tumor DNA (ctDNA) le

      4/24/25 8:05:00 AM ET
      $GH
      $PFE
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $PFE
    $RCKT
    Financials

    Live finance-specific insights

    See more
    • Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance

      Delivers Robust Earnings Performance, Successfully Navigating a Dynamic Environment Made Significant Progress Strengthening the R&D Organization On Track to Exceed Net Cost Savings Targets Pfizer Inc. (NYSE:PFE) reported financial results for the first quarter of 2025 and reaffirmed its 2025 financial guidance(1). EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "We continued to execute with focus and discipline against our strategic priorities, including strengthening our R&D organization and driving improved productivity. With the underlying strength of our business, we believe we can be agile in navigating an uncertain and volatile external environment." Dav

      4/29/25 6:45:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Declares Second-Quarter 2025 Dividend

      Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 second-quarter 2025 dividend on the company's common stock, payable June 13, 2025, to holders of the Common Stock of record at the close of business on May 9, 2025. The second-quarter 2025 cash dividend will be the 346th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, develo

      4/23/25 4:40:00 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts

      Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, April 29, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's First Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the conference

      3/18/25 10:00:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PFE
    $RCKT
    Leadership Updates

    Live Leadership Updates

    See more
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations
    • FoRx Therapeutics Appoints Chief Medical Officer and Provides an Update on Its Lead Development Candidate

      Industry veteran in clinical development of oncology therapeutics, Dr. Jens Wurthner, PhD, joins as Chief Medical Officer Lead development candidate, FORX-428, a PARG inhibitor for solid tumors, maintains progress toward IND submission by mid-2025 FoRx Therapeutics AG, a Swiss-based company committed to discovering and developing innovative drugs targeting cancer-relevant DDR (DNA Damage Response) pathways, today announced that it has appointed Jens Würthner, MD PhD, as Chief Medical Officer. He is further strengthening FoRx Therapeutics' existing management team with CEO Tarig Bashir, CSO Frank Zenke, and Head of Chemistry Ulrich Lücking. Jens Würthner has 20+ years of clinical devel

      2/26/25 9:00:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • GeminiBio Appoints Mike Stella to Board

      Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

      2/18/25 9:00:00 AM ET
      $AMGN
      $GSK
      $JNJ
      $MRK
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Industrial Machinery/Components